Getty/DuxX
09 July 2021
Healthcare device manufacturer, Luneau Technology, and medical device company, Optovue, have formed a definitive agreement to merge.
The companies suggest the merger will create a “complete offering” for eye care professionals, bringing together its technologies and with a key focus on telehealth solutions.
CEO of Luneau Technology, Dr Marc Abitbol, will lead the combined company and Peter Wyles will continue in his role as CEO of Optovue.
The two companies will continue to deliver products through their existing channels and will initially focus on sharing good practice.
In addition to providing a full product range to customers, it is suggested the merger would enable the companies to leverage industry expertise and strengthen their international reach, with a joint vision of becoming the “first-choice partner for primary eye care” and improving access to visual health.
Luneau Technology develops and manufactures devices for eye care professionals, with its flagship brand, Visionix, specialising in diagnosis and refraction, while Optovue is focused on the advancement and commercialisation of high-speed optical coherence tomography (OCT) and OCT Angiography technology.
Commenting on the merger, Abitbol said: “It will benefit us, our clients and patients. OCT is the next technology we were looking for, and it fits beautifully into our product offering.
“By joining forces with Optovue, we’ll be able to offer a significantly improved customer experience with full front- and back-of-the-eye platforms,” he added.
Optovue’s Wyles suggested the merger makes sense for both companies, continuing: “We are thrilled to work together toward our common vision, while at the same time, significantly optimising the customer experience.”
The merger remains subject to customary conditions for completion and legal approvals.
The companies suggest the merger will create a “complete offering” for eye care professionals, bringing together its technologies and with a key focus on telehealth solutions.
CEO of Luneau Technology, Dr Marc Abitbol, will lead the combined company and Peter Wyles will continue in his role as CEO of Optovue.
The two companies will continue to deliver products through their existing channels and will initially focus on sharing good practice.
In addition to providing a full product range to customers, it is suggested the merger would enable the companies to leverage industry expertise and strengthen their international reach, with a joint vision of becoming the “first-choice partner for primary eye care” and improving access to visual health.
Luneau Technology develops and manufactures devices for eye care professionals, with its flagship brand, Visionix, specialising in diagnosis and refraction, while Optovue is focused on the advancement and commercialisation of high-speed optical coherence tomography (OCT) and OCT Angiography technology.
Commenting on the merger, Abitbol said: “It will benefit us, our clients and patients. OCT is the next technology we were looking for, and it fits beautifully into our product offering.
“By joining forces with Optovue, we’ll be able to offer a significantly improved customer experience with full front- and back-of-the-eye platforms,” he added.
Optovue’s Wyles suggested the merger makes sense for both companies, continuing: “We are thrilled to work together toward our common vision, while at the same time, significantly optimising the customer experience.”
The merger remains subject to customary conditions for completion and legal approvals.
Comments (0)
You must be logged in to join the discussion. Log in